

Special Issue

Lipoproteins and Cardiovascular Diseases

Message from the Guest Editors

Lipoproteins are lipid transport molecules that transport plasma lipids and represent risk factors for cardiovascular disease and other metabolic diseases. Understanding lipoproteins and the different ways in which to manipulate their metabolism is an essential step for preventing cardiovascular disease and morbidity in the general population. The aim of this Special Issue is to provide an update on the latest experimental research focused on lipoproteins and cardiovascular disease, including recent therapeutic strategies for lowering LDL cholesterol or lipoprotein a. We welcome papers focused on lipoproteins (small dense LDL, apolipoprotein B, lipoprotein a) and cardiovascular disease, including reviews and experimental studies.

Guest Editors

Dr. Marco Gentile

Dipartimento di Medicina e Chirurgia, Università degli Studi di Napoli Federico II, Via Pansini 5, 80131 Napoli, Italy

Dr. Gabriella Iannuzzo

Università degli Studi di Napoli Federico II, Dipartimento di Medicina e Chirurgia, Via Pansini 5, 80131 Napoli, Italy

Deadline for manuscript submissions

closed (31 March 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/69505

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).